Difference between revisions of "Soft tissue sarcoma"
m |
m (Text replace - ", et al. " to " et al. ") |
||
Line 9: | Line 9: | ||
==Dacarbazine (DTIC)== | ==Dacarbazine (DTIC)== | ||
− | ===Regimen, Buesa | + | ===Regimen, Buesa et al. 1991=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 41: | Line 41: | ||
*[[Doxorubicin (Adriamycin)]] 75 mg/m2 IV bolus once on day 1 | *[[Doxorubicin (Adriamycin)]] 75 mg/m2 IV bolus once on day 1 | ||
− | '''21-day cycles x up to 6 cycles, until progression of disease, unacceptable toxicity, or patient refusal'''. In Mouridsen | + | '''21-day cycles x up to 6 cycles, until progression of disease, unacceptable toxicity, or patient refusal'''. In Mouridsen et al. 1987, treatment was given until progression of disease, unacceptable toxicity, or cumulative doxorubicin dosage of 550 mg/m2, though the ultimate decision to stop treatment based on cumulative doxorubicin dosage was at the discretion of the treating physician. |
===References=== | ===References=== | ||
− | # Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D | + | # Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477-83. '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/3479329 PubMed] |
# Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103-12. doi: 10.1080/13577140020008066. [http://www.hindawi.com/journals/srcm/2000/149793/abs/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18521288 PubMed] | # Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103-12. doi: 10.1080/13577140020008066. [http://www.hindawi.com/journals/srcm/2000/149793/abs/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/18521288 PubMed] | ||
# Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50. [http://jco.ascopubs.org/content/25/21/3144.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17634494 PubMed] | # Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50. [http://jco.ascopubs.org/content/25/21/3144.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17634494 PubMed] | ||
Line 64: | Line 64: | ||
===References=== | ===References=== | ||
− | # Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D | + | # Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477-83. '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/3479329 PubMed] |
==Ifosfamide (Ifex)== | ==Ifosfamide (Ifex)== | ||
− | ===Regimen #1, van Oosterom | + | ===Regimen #1, van Oosterom et al. 2002=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 89: | Line 89: | ||
*1 liter of fluid PO two times per day on days 1 to 3, taken 4 and 8 hours after completion of ifosfamide and mesna | *1 liter of fluid PO two times per day on days 1 to 3, taken 4 and 8 hours after completion of ifosfamide and mesna | ||
− | ===Regimen #2, Lorigan | + | ===Regimen #2, Lorigan et al. 2007 - short infusion, Ifos 3=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 111: | Line 111: | ||
*Patient with somnolesence or other signs of encephalopathy with ifosfamide received methylene blue 50 mg IV every 4 hours until resolution of symptoms. During cycles thereafter, patients would receive methylene blue 50 mg IV every 4 hours, starting 4 hours prior to ifosfamide on day 1, continuing until 72 hours after completion | *Patient with somnolesence or other signs of encephalopathy with ifosfamide received methylene blue 50 mg IV every 4 hours until resolution of symptoms. During cycles thereafter, patients would receive methylene blue 50 mg IV every 4 hours, starting 4 hours prior to ifosfamide on day 1, continuing until 72 hours after completion | ||
− | ===Regimen #3, Lorigan | + | ===Regimen #3, Lorigan et al. 2007 - continuous infusion, Ifos 9=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 139: | Line 139: | ||
==Pazopanib (Votrient)== | ==Pazopanib (Votrient)== | ||
− | ===Regimen, van der Graaf | + | ===Regimen, van der Graaf et al. 2012 (PALETTE)=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 173: | Line 173: | ||
==Temozolomide (Temodar)== | ==Temozolomide (Temodar)== | ||
− | ===Regimen #1, Talbot | + | ===Regimen #1, Talbot et al. 2003=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 189: | Line 189: | ||
*[[Antiemesis|Antiemetics]] "prescribed as clinically indicated by the treating physician" | *[[Antiemesis|Antiemetics]] "prescribed as clinically indicated by the treating physician" | ||
− | ===Regimen #2, Garcia del Muro | + | ===Regimen #2, Garcia del Muro et al. 2005=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 215: | Line 215: | ||
AIM: '''<u>A</u>'''driamycin, '''<u>I</u>'''fosfamide, '''<u>M</u>'''esna | AIM: '''<u>A</u>'''driamycin, '''<u>I</u>'''fosfamide, '''<u>M</u>'''esna | ||
− | ===Regimen #1, Patel | + | ===Regimen #1, Patel et al. 1998 - 5-day course, lower dose doxorubicin - AI 75/10=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 235: | Line 235: | ||
*If febrile neutropenia occurs, [[Filgrastim (Neupogen)|G-CSF]] is used in subsequent cycles | *If febrile neutropenia occurs, [[Filgrastim (Neupogen)|G-CSF]] is used in subsequent cycles | ||
− | ===Regimen #2, Patel | + | ===Regimen #2, Patel et al. 1998 - 4-day course, higher dose doxorubicin - AI 90/10=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 286: | Line 286: | ||
==Gemcitabine (Gemzar) & Docetaxel (Taxotere)== | ==Gemcitabine (Gemzar) & Docetaxel (Taxotere)== | ||
− | ===Regimen #1, Hensley | + | ===Regimen #1, Hensley et al. 2002 & 2008 - no prior radiation=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 298: | Line 298: | ||
*[[Docetaxel (Taxotere)]] 100 mg/m2 IV over 1 hour once on day 8, given second | *[[Docetaxel (Taxotere)]] 100 mg/m2 IV over 1 hour once on day 8, given second | ||
− | '''21-day cycles x 6 to 8 cycles, given until progression of disease or unacceptable toxicity'''; Hensley | + | '''21-day cycles x 6 to 8 cycles, given until progression of disease or unacceptable toxicity'''; Hensley et al. 2008 did not specify a maximum number of cycles |
Supportive medications: | Supportive medications: | ||
Line 307: | Line 307: | ||
**[[Pegfilgrastim (Neulasta)]] 6 mg SC once on either day 9 or 10 (only one dose given) | **[[Pegfilgrastim (Neulasta)]] 6 mg SC once on either day 9 or 10 (only one dose given) | ||
− | ===Regimen #2, Hensley | + | ===Regimen #2, Hensley et al. 2002 & 2008 - patients who received prior radiation=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 319: | Line 319: | ||
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 1 hour once on day 8, given second | *[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 1 hour once on day 8, given second | ||
− | '''21-day cycles x 6 to 8 cycles, given until progression of disease or unacceptable toxicity'''; Hensley | + | '''21-day cycles x 6 to 8 cycles, given until progression of disease or unacceptable toxicity'''; Hensley et al. 2008 did not specify a maximum number of cycles |
Supportive medications: | Supportive medications: | ||
Line 334: | Line 334: | ||
==Gemcitabine (Gemzar) & Vinorelbine (Navelbine)== | ==Gemcitabine (Gemzar) & Vinorelbine (Navelbine)== | ||
− | ===Regimen, Dileo | + | ===Regimen, Dileo et al. 2007=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 354: | Line 354: | ||
==Denosumab (Xgeva)== | ==Denosumab (Xgeva)== | ||
− | ===Regimen, Thomas, et. al 2010 & Branstetter | + | ===Regimen, Thomas, et. al 2010 & Branstetter et al. 2012=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 377: | Line 377: | ||
=GIST (Gastrointestinal Stromal Tumor) - neoadjuvant therapy= | =GIST (Gastrointestinal Stromal Tumor) - neoadjuvant therapy= | ||
==Imatinib (Gleevec)== | ==Imatinib (Gleevec)== | ||
− | ===Regimen, Eisenberg | + | ===Regimen, Eisenberg et al. 2009 (RTOG 0132)=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 396: | Line 396: | ||
==Imatinib (Gleevec)== | ==Imatinib (Gleevec)== | ||
− | ===Regimen #1, Joensuu | + | ===Regimen #1, Joensuu et al. 2012 - 3 years of treatment=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 410: | Line 410: | ||
'''36-month course, treatment started within 12 weeks after surgery''' | '''36-month course, treatment started within 12 weeks after surgery''' | ||
− | ===Regimen #2, Dematteo | + | ===Regimen #2, Dematteo et al. 2009 - 1 year of treatment=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 445: | Line 445: | ||
=GIST (Gastrointestinal Stromal Tumor) - metastatic or unresectable disease= | =GIST (Gastrointestinal Stromal Tumor) - metastatic or unresectable disease= | ||
==Imatinib (Gleevec)== | ==Imatinib (Gleevec)== | ||
− | ===Regimen #1, Blanke | + | ===Regimen #1, Blanke et al. 2008=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 464: | Line 464: | ||
'''given until progression of disease or unacceptable toxicity''' | '''given until progression of disease or unacceptable toxicity''' | ||
− | ===Regimen #2, Verweij | + | ===Regimen #2, Verweij et al. 2003=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 477: | Line 477: | ||
'''given until progression of disease or unacceptable toxicity''' | '''given until progression of disease or unacceptable toxicity''' | ||
− | ===Regimen #3, Demetri | + | ===Regimen #3, Demetri et al. 2002=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 544: | Line 544: | ||
==Temozolomide (Temodar)== | ==Temozolomide (Temodar)== | ||
− | *Regimen is the same as [[#Temozolomide_.28Temodar.29|Temozolomide (Temodar) single-agent therapy in soft tissue sarcoma, Garcia del Muro | + | *Regimen is the same as [[#Temozolomide_.28Temodar.29|Temozolomide (Temodar) single-agent therapy in soft tissue sarcoma, Garcia del Muro et al. 2005]] |
=Angiosarcoma= | =Angiosarcoma= | ||
Line 583: | Line 583: | ||
*[[Dexamethasone (Decadron)]] 8 mg IV once prior to paclitaxel | *[[Dexamethasone (Decadron)]] 8 mg IV once prior to paclitaxel | ||
*Cimetidine (Tagamet) 200 mg IV once prior to paclitaxel | *Cimetidine (Tagamet) 200 mg IV once prior to paclitaxel | ||
− | *Dexchlorpheniramine (note: was spelled as dexchloropheramine in the Penel | + | *Dexchlorpheniramine (note: was spelled as dexchloropheramine in the Penel et al. 2008) (Polaramine) 5 mg IV once prior to paclitaxel |
*"Standard [[Antiemesis|antiemetics]] (mainly metoclopramide) were prescribed as clinically indicated by the treating physician" | *"Standard [[Antiemesis|antiemetics]] (mainly metoclopramide) were prescribed as clinically indicated by the treating physician" | ||
Line 594: | Line 594: | ||
ABV: '''<u>A</u>'''driamycin, '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine | ABV: '''<u>A</u>'''driamycin, '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine | ||
− | ===Regimen #1, Northfelt | + | ===Regimen #1, Northfelt et al. 1998=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 612: | Line 612: | ||
*"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators." | *"Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators." | ||
− | ===Regimen #2, Gill | + | ===Regimen #2, Gill et al. 1996=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 621: | Line 621: | ||
border-style:solid;">Phase III</span> | border-style:solid;">Phase III</span> | ||
− | ''Gill | + | ''Gill et al. 1996 did not clearly say in the paper when these drugs were given, but this schedule is assumed based on the Northfelt et al. 1998 ABV regimen.'' |
*[[Doxorubicin (Adriamycin)]] 10 mg/m2 IV once on day 1 | *[[Doxorubicin (Adriamycin)]] 10 mg/m2 IV once on day 1 | ||
*[[Bleomycin (Blenoxane)]] 15 units IV on day 1 | *[[Bleomycin (Blenoxane)]] 15 units IV on day 1 | ||
Line 664: | Line 664: | ||
==Daunorubicin liposomal (DaunoXome)== | ==Daunorubicin liposomal (DaunoXome)== | ||
− | ===Regimen, Gill | + | ===Regimen, Gill et al. 1996=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span | ||
Line 685: | Line 685: | ||
==Doxorubicin liposomal (Doxil)== | ==Doxorubicin liposomal (Doxil)== | ||
− | ===Regimen, Northfelt | + | ===Regimen, Northfelt et al. 1998=== |
Level of Evidence: | Level of Evidence: | ||
<span | <span |
Revision as of 23:38, 17 October 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Single-agent regimens
Dacarbazine (DTIC)
Regimen, Buesa et al. 1991
Level of Evidence: Phase II
- Dacarbazine (DTIC) 1200 mg/m2 in 200 mL normal saline IV over 20 minutes once on day 1
21-day cycles, given until progression of disease
Supportive medications:
- Calcium gluconate (10% solution) 5 mL IV every 10 minutes x 3 doses (total of 15 mL) after the start of dacarbazine; 2 additional doses of calcium gluconate (10% solution) 5 mL IV every 10 minutes were given to patients whose systolic blood pressure decreased below 80 mmHg or heart rate ≥160 beat/minute.
References
- Buesa JM, Mouridsen HT, van Oosterom AT, Verweij J, Wagener T, Steward W, Poveda A, Vestlev PM, Thomas D, Sylvester R. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991 Apr;2(4):307-9. link to original article contains verified protocol PubMed
Doxorubicin (Adriamycin)
Regimen
Level of Evidence: Phase III
- Doxorubicin (Adriamycin) 75 mg/m2 IV bolus once on day 1
21-day cycles x up to 6 cycles, until progression of disease, unacceptable toxicity, or patient refusal. In Mouridsen et al. 1987, treatment was given until progression of disease, unacceptable toxicity, or cumulative doxorubicin dosage of 550 mg/m2, though the ultimate decision to stop treatment based on cumulative doxorubicin dosage was at the discretion of the treating physician.
References
- Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477-83. contains verified protocol PubMed
- Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103-12. doi: 10.1080/13577140020008066. link to original article PubMed
- Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50. link to original article contains verified protocol PubMed
Epirubicin (Ellence)
Regimen
Level of Evidence: Phase III
- Epirubicin (Ellence) 75 mg/m2 IV bolus once on day 1
21-day cycles, given until progression of disease, unacceptable toxicity, or cumulative epirubicin dosage of 550 mg/m2 (though the ultimate decision to stop treatment based on cumulative epirubicin dosage was at the discretion of the treating physician)
References
- Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, van Oosterom AT, Buesa J, Pinedo HM, Thomas D et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477-83. contains verified protocol PubMed
Ifosfamide (Ifex)
Regimen #1, van Oosterom et al. 2002
Level of Evidence: Phase II
- Ifosfamide (Ifex) 3000 mg/m2 IV over 4 hours once per day on days 1 to 3
- Each day's dose of ifosfamide is dissolved in 125 mL sterile water per 1000 mg of ifosfamide, mixed together with mesna in an additional 1 liter of dextrose/saline
- Mesna (Mesnex) 600 mg/m2 IV bolus once on day 1, immediately prior to mesna/ifosfamide infusion
- Mesna (Mesnex) 1500 mg/m2 IV over 4 hours on days 1 to 3, given together with ifosfamide
- Mesna (Mesnex) 500 mg/m2 IV two times per day on days 1 to 3, given at 4 and 8 hours after completion of ifosfamide and mesna
21-day cycles x at least 2 cycles, except in cases of rapid disease progression; continued until disease progression or unacceptable toxicity or patient refusal
Supportive medications:
- "Antiemetics were prescribed according to local conventions"
- 1 liter of fluid PO two times per day on days 1 to 3, taken 4 and 8 hours after completion of ifosfamide and mesna
Regimen #2, Lorigan et al. 2007 - short infusion, Ifos 3
Level of Evidence: Phase III
- Ifosfamide (Ifex) 3000 mg/m2 IV over 4 hours on days 1 to 3, given together with mesna
- Each day's dose of ifosfamide is mixed together with mesna in 1 liter of normal saline
- Mesna (Mesnex) 600 mg/m2 IV bolus once on day 1, immediately prior to mesna/ifosfamide infusion
- Mesna (Mesnex) 1500 mg/m2 IV over 4 hours on days 1 to 3, given together with ifosfamide
- Mesna (Mesnex) 1200 mg/m2 IV two times per day on days 1 to 3, given at 4 and 8 hours after completion of ifosfamide and mesna
- An alternative is to use oral mesna instead of intravenous: Mesna (Mesnex) 1200 mg/m2 PO two times per day on days 1 to 3, given at 2 and 6 hours after completion of ifosfamide and mesna
21-day cycles x up to 6 cycles, until progression of disease, unacceptable toxicity, or patient refusal
Supportive medications:
- Sodium bicarbonate 150 mmol IV once per day on days 1 to 3
- Patient with somnolesence or other signs of encephalopathy with ifosfamide received methylene blue 50 mg IV every 4 hours until resolution of symptoms. During cycles thereafter, patients would receive methylene blue 50 mg IV every 4 hours, starting 4 hours prior to ifosfamide on day 1, continuing until 72 hours after completion
Regimen #3, Lorigan et al. 2007 - continuous infusion, Ifos 9
Level of Evidence: Phase III
- Ifosfamide (Ifex) 3000 mg/m2/day IV continuous infusion over 72 hours (total dose per cycle: 9000 mg/m2) on days 1 to 3, given together with mesna
- Each day's dose of ifosfamide is mixed together with mesna in 3 liters of normal saline
- Mesna (Mesnex) 600 mg/m2 IV bolus once on day 1, immediately prior to mesna/ifosfamide infusion
- Mesna (Mesnex) 3000 mg/m2/day IV continuous infusion over 72 hours (total dose per cycle: 9000 mg/m2) on days 1 to 3, given together with ifosfamide
- Mesna (Mesnex) 1800 mg/m2 IV over 12 hours once on day 4, starting after completion of ifosfamide and mesna
- An alternative is to use oral mesna instead of intravenous: Mesna (Mesnex) 1200 mg/m2 PO three times on day 4, given 0, 2, and 6 hours after completion of ifosfamide and mesna
21-day cycles x up to 6 cycles, until progression of disease, unacceptable toxicity, or patient refusal
Supportive medications:
- Sodium bicarbonate 150 mmol IV once per day on days 1 to 3
- Patient with somnolesence or other signs of encephalopathy with ifosfamide received methylene blue 50 mg IV every 4 hours until resolution of symptoms. During cycles thereafter, patients would receive methylene blue 50 mg IV every 4 hours, starting 4 hours prior to ifosfamide on day 1, continuing until 72 hours after completion
References
- van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, Svancarova L, Spooner D, Hermans C, Van Glabbeke M, Verweij J; EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002 Dec;38(18):2397-406 link to original article contains verified protocol PubMed content property of HemOnc.org
- Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50. link to original article contains verified protocol PubMed
Pazopanib (Votrient)
Regimen, van der Graaf et al. 2012 (PALETTE)
Level of Evidence: Phase III
- Pazopanib (Votrient) 800 mg PO once per day
given until progression of disease, unacceptable toxicity, withdrawal of consent, or death
References
- van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Sch�ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. link to original article contains verified protocol PubMed
Placebo
Regimen
Level of Evidence: Phase III
No treatment. Used as a comparator arm and here for reference purposes only.
References
- van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Sch�ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. link to original article contains verified protocol PubMed
Temozolomide (Temodar)
Regimen #1, Talbot et al. 2003
Level of Evidence: Phase II
- Temozolomide (Temodar) 200 mg/m2 (doses rounded up if needed to next available dosage based on capsule doses) PO once on day 1, on an empty stomach; then 12 hours later, Temozolomide (Temodar) 90 mg/m2 PO once every 12 hours x 9 doses (total of 10 doses per cycle) on days 1 to 5, on an empty stomach
28-day cycles, given until progression of disease x 1 year; patients on study could be reconsented to receive therapy beyond 1 year
Supportive medications:
- Antiemetics "prescribed as clinically indicated by the treating physician"
Regimen #2, Garcia del Muro et al. 2005
Level of Evidence: Phase II
- Temozolomide (Temodar) 100 mg/m2 PO once per day on days 1 to 42 (6 weeks), with no food 1 hour before and after temozolomide doses
- Initial dose used in the study was 75 mg/m2, but due to lack of toxicity, protocol was amended to use 100 mg/m2 doses
9-week cycles x up to 3 cycles, progression of disease, or unacceptable toxicity
Supportive medications:
- "Antiemetics, mainly oral metoclopramide and ondansetron, were prescribed as clinically indicated by the treating physician"
References
- Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, Troxel AB, Taub RN. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 2003 Nov 1;98(9):1942-6. link to original article contains verified protocol PubMed
- Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J; Spanish Group for Research on Sarcomas. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005 Oct 15;104(8):1706-12. link to original article contains verified protocol PubMed
Combination regimens
AIM
AIM: Adriamycin, Ifosfamide, Mesna
Regimen #1, Patel et al. 1998 - 5-day course, lower dose doxorubicin - AI 75/10
Level of Evidence: Pilot, <20 patients reported
- Doxorubicin (Adriamycin) 25 mg/m2/day IV continuous infusion over 72 hours (total dose per cycle: 75 mg/m2) on days 1 to 3
- Ifosfamide (Ifex) 2000 mg/m2 IV over 2 hours once per day on days 1 to 5 (total dose per cycle: 10,000 mg/m2)
- Mesna (Mesnex) 400 mg/m2 IV once on day 1, given simultaneously with the first dose of ifosfamide
- Mesna (Mesnex) 1200 mg/m2/day IV continuous infusion over 5 days (total dose per cycle: 6000 mg/m2) on days 1 to 5
- Each day's dose of mesna is given in 2 liters of D5W with 100 mEq/L sodium acetate, 20 mEq/L potassium acetate, and 4 mEq/L magnesium sulfate
21-day cycles, given until maximum response, 6 cycles of therapy, progression of disease, or unacceptable toxicity
Supportive medications:
- If febrile neutropenia occurs, G-CSF is used in subsequent cycles
Regimen #2, Patel et al. 1998 - 4-day course, higher dose doxorubicin - AI 90/10
Level of Evidence: Pilot, <20 patients reported
- Doxorubicin (Adriamycin) 30 mg/m2/day IV continuous infusion over 72 hours (total dose per cycle: 90 mg/m2) on days 1 to 3
- Ifosfamide (Ifex) 2500 mg/m2 IV over 3 hours once per day on days 1 to 4 (total dose per cycle: 10,000 mg/m2)
- Mesna (Mesnex) 500 mg/m2 IV once on day 1, given simultaneously with the first dose of ifosfamide
- Mesna (Mesnex) 1500 mg/m2/day IV continuous infusion over 4 days (total dose per cycle: 6000 mg/m2) on days 1 to 4
- Each day's dose of mesna is given in 2 liters of D5W with 100 mEq/L sodium acetate, 20 mEq/L potassium acetate, and 4 mEq/L magnesium sulfate
21-day cycles, given until maximum response, 6 cycles of therapy, progression of disease, or unacceptable toxicity
Supportive medications:
- G-CSF 5 mcg/kg (dose rounded to 300 or 480 mcg) SC once per day, starting on day 5, given until ANC is at least 10,000
References
- Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998 Jun;21(3):317-21. link to original article contains verified protocol PubMed
Epirubicin (Ellence) & Ifosfamide (Ifex)
Regimen
Level of Evidence: Phase II
- Epirubicin (Ellence) 45 mg/m2/day IV continuous infusion over 2 days (total dose per cycle: 90 mg/m2) on days 2-3
- Ifosfamide (Ifex) 2500 mg/m2/day IV continuous infusion over 5 days (total dose per cycle: 12,500 mg/m2) on days 1 to 5, given together with mesna
- Each day's dose of ifosfamide is mixed together with mesna in 3 liters of "fluids with electrolytes"
- Mesna (Mesnex) 1500 mg/m2 IV continuous infusion over 5 days (total dose per cycle: 7500 mg/m2) on days 1 to 5, given together with ifosfamide
21-day cycles
Supportive medications:
- G-CSF 5 mcg/kg SC once per day on days 6 to 15 or "until recovery of leukocytes"
- Ondansetron (Zofran) 8-24 mg per day prn nausea
- Dexamethasone (Decadron) (dose/schedule not specified) for antiemesis if necessary
References
- Reichardt P, Tilgner J, Hohenberger P, D�rken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998 Apr;16(4):1438-43. link to original article contains verified protocol PubMed
Gemcitabine (Gemzar) & Docetaxel (Taxotere)
Regimen #1, Hensley et al. 2002 & 2008 - no prior radiation
Level of Evidence: Phase II
- Gemcitabine (Gemzar) 900 mg/m2 IV over 90 minutes once per day on days 1 & 8, given first
- Docetaxel (Taxotere) 100 mg/m2 IV over 1 hour once on day 8, given second
21-day cycles x 6 to 8 cycles, given until progression of disease or unacceptable toxicity; Hensley et al. 2008 did not specify a maximum number of cycles
Supportive medications:
- Dexamethasone (Decadron) 8 mg PO BID on days 7-9 (the day before, the day of, and day after docetaxel)
- Patients could receive diuretics at physician discretion for peripheral edema related to docetaxel
- One of the following growth factors (varies depending on reference):
- G-CSF 150 mcg/m2 (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC >1200/uL on two separate measurements
- Pegfilgrastim (Neulasta) 6 mg SC once on either day 9 or 10 (only one dose given)
Regimen #2, Hensley et al. 2002 & 2008 - patients who received prior radiation
Level of Evidence: Phase II
- Gemcitabine (Gemzar) 675 mg/m2 IV over 90 minutes once per day on days 1 & 8, given first
- Docetaxel (Taxotere) 75 mg/m2 IV over 1 hour once on day 8, given second
21-day cycles x 6 to 8 cycles, given until progression of disease or unacceptable toxicity; Hensley et al. 2008 did not specify a maximum number of cycles
Supportive medications:
- Dexamethasone (Decadron) 8 mg PO BID on days 7-9 (the day before, the day of, and day after docetaxel)
- Patients could receive diuretics at physician discretion for peripheral edema related to docetaxel
- One of the following growth factors (varies depending on reference):
- G-CSF 150 mcg/m2 (dose rounded to 300 or 480 mcg) SC once per day on days 9 to 15 as primary neutropenia prophylaxis; could be stopped before day 15 if ANC >1200/uL on two separate measurements
- Pegfilgrastim (Neulasta) 6 mg SC once on either day 9 or 10 (only one dose given)
References
- Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002 Jun 15;20(12):2824-31. link to original article contains verified protocol PubMed
- Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008 Jun;109(3):329-34. link to original article contains verified protocol PubMed
Regimen, Dileo et al. 2007
Level of Evidence: Phase II
- Gemcitabine (Gemzar) 800 mg/m2 IV over 90 minutes once per day on days 1 & 8
- Vinorelbine (Navelbine) 25 mg/m2 IV over 10 minutes once per day on days 1 & 8
21-day cycles, given until progression of disease or unacceptable toxicity
Reference
- Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 1;109(9):1863-9. link to original article contains verified protocol PubMed
Giant-cell tumor of bone
Denosumab (Xgeva)
Regimen, Thomas, et. al 2010 & Branstetter et al. 2012
Level of Evidence: Phase II
- Denosumab (Xgeva) 120 mg SC once per day on days 1, 8, 15 of cycle 1; then on subsequent cycles Denosumab (Xgeva) 120 mg SC once on day 1
28-day cycles, given until complete tumor resection, progression of disease, or patient choice
Supportive medications (per Thomas, et. al 2010):
- Calcium 500 mg PO once per day
- Vitamin D 400 IU PO once per day
References
- Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. link to original article contains verified protocol PubMed
- Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578. Epub 2012 Jun 18. link to original article contains verified protocol PubMed
GIST (Gastrointestinal Stromal Tumor) - neoadjuvant therapy
Imatinib (Gleevec)
Regimen, Eisenberg et al. 2009 (RTOG 0132)
Level of Evidence: Phase II
- Imatinib (Gleevec) 600 mg PO once per day
given for 8-12 weeks prior to surgery, stopped on the day prior to surgery, resumed as soon as possible postoperatively, and continued for 2 years as postoperative adjuvant therapy
References
- Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009 Jan 1;99(1):42-7. link to original article contains verified protocol PubMed
GIST (Gastrointestinal Stromal Tumor) - adjuvant therapy
Imatinib (Gleevec)
Regimen #1, Joensuu et al. 2012 - 3 years of treatment
Level of Evidence: Phase III
Showed improved recurrence-free survival with 36 months of therapy as compared to 12 months of therapy.
- Imatinib (Gleevec) 400 mg PO once per day
36-month course, treatment started within 12 weeks after surgery
Regimen #2, Dematteo et al. 2009 - 1 year of treatment
Level of Evidence: Phase III
- Imatinib (Gleevec) 400 mg PO once per day
1-year course; treatment started within 12 weeks after surgery
References
- Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104. link to original article contains verified protocol PubMed
- Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Sch�tte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alveg�rd T, Reichardt P. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347. link to original article contains verified protocol PubMed
Placebo
Regimen
Level of Evidence: Phase III
No treatment. Used as a comparator arm and here for reference purposes only.
References
- Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104. link to original article contains verified protocol PubMed
GIST (Gastrointestinal Stromal Tumor) - metastatic or unresectable disease
Imatinib (Gleevec)
Regimen #1, Blanke et al. 2008
Level of Evidence: Phase III
Standard dose therapy
- Imatinib (Gleevec) 400 mg PO once per day
given until progression of disease or unacceptable toxicity; patients who progressed on imatinib 400 mg PO once per day could receive high-dose therapy, as described below
High-dose therapy
- Imatinib (Gleevec) 400 mg PO twice per day
given until progression of disease or unacceptable toxicity
Regimen #2, Verweij et al. 2003
Level of Evidence: Phase II
- Imatinib (Gleevec) 400 mg PO twice a day, taken after a meal
given until progression of disease or unacceptable toxicity
Regimen #3, Demetri et al. 2002
Level of Evidence: Phase III
- Imatinib (Gleevec) 400 mg PO once per day, taken with food
References
- Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472-80. link to original article contains verified protocol PubMed
- Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003 Sep;39(14):2006-11. link to original article contains verified protocol PubMed
- Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452. link to original article contains verified protocol PubMed
- Meta-analysis: Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010 Mar 1;28(7):1247-53. doi: 10.1200/JCO.2009.24.2099. Epub 2010 Feb 1. link to original article PubMed
Placebo
Regimen
Level of Evidence: Phase III
No treatment. Used as a comparator arm and here for reference purposes only.
References
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. link to original article contains verified protocol PubMed
- Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Sch�ffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. link to original article contains verified protocol PubMed
Regorafenib (Stivarga)
Regimen (GRID)
Level of Evidence: Phase III
Patients in this study already had treatment failure with imatinib and sunitinib.
- Regorafenib (Stivarga) 160 mg PO once per day on days 1 to 21
28-day cycles, given until progression of disease or unacceptable toxicity
References
- Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Sch�ffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. link to original article contains verified protocol PubMed
Sunitinib (Sutent)
Regimen
Patients in this study had treatment failure with imatinib.
- Sunitinib (Sutent) 50 mg PO once per day on days 1 to 28
- Dose may be decreased to 37.5 mg or 25 mg depending on tolerability
42-day cycles, given until progression of disease or unacceptable toxicity
References
- Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38. link to original article contains verified protocol PubMed
- Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009 Jan 20;27(3):439-45. doi: 10.1200/JCO.2008.17.2742. Epub 2008 Dec 8. link to original article contains verified protocol PubMed
Temozolomide (Temodar)
- Regimen is the same as Temozolomide (Temodar) single-agent therapy in soft tissue sarcoma, Garcia del Muro et al. 2005
Angiosarcoma
Bevacizumab (Avastin)
Regimen, Agulnik et al. 2013
Level of Evidence: Phase II
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles, given until progression of disease, intolerance, unacceptable toxicity, patient refusal, or physician discretion
References
- Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. doi: 10.1093/annonc/mds237. link to original article contains verified protocol PubMed
Paclitaxel (Taxol)
Regimen, Penel et al. 2008 (ANGIOTAX)
Level of Evidence: Phase II
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
28-day cycles x 6 cycles, given until progression of disease or unacceptable toxicity
Supportive medications:
- Dexamethasone (Decadron) 8 mg IV once prior to paclitaxel
- Cimetidine (Tagamet) 200 mg IV once prior to paclitaxel
- Dexchlorpheniramine (note: was spelled as dexchloropheramine in the Penel et al. 2008) (Polaramine) 5 mg IV once prior to paclitaxel
- "Standard antiemetics (mainly metoclopramide) were prescribed as clinically indicated by the treating physician"
References
- Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. doi: 10.1200/JCO.2008.17.3146. Epub 2008 Sep 22. link to original article contains verified protocol PubMed
HIV/AIDS-associated Kaposi's Sarcoma
ABV
ABV: Adriamycin, Bleomycin, Vincristine
Regimen #1, Northfelt et al. 1998
Level of Evidence: Phase III
- Doxorubicin (Adriamycin) 20 mg/m2 IV once on day 1
- Bleomycin (Blenoxane) 10 mg/m2 IV once on day 1
- Vincristine (Oncovin) 1 mg IV once on day 1
14-day cycles x up to 6 cycles
Supportive medications:
- "Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators."
Regimen #2, Gill et al. 1996
Level of Evidence: Phase III
Gill et al. 1996 did not clearly say in the paper when these drugs were given, but this schedule is assumed based on the Northfelt et al. 1998 ABV regimen.
- Doxorubicin (Adriamycin) 10 mg/m2 IV once on day 1
- Bleomycin (Blenoxane) 15 units IV on day 1
- Vincristine (Oncovin) 1 mg IV on day 1
14-day cycles x minimum of 2 cycles; given until complete remission, unacceptable toxicity, disease progression, patient refusal, or death
Supportive medications:
- "No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator"
References
- Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M,Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. link to original article contains verified protocol PubMed
- Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. link to original article contains verified protocol PubMed
Bevacizumab (Avastin)
Regimen, Uldrick et al. 2012
Level of Evidence: Phase II
Loading dose
- Bevacizumab (Avastin) 15 mg/kg IV once as a loading dose; start regular therapy 7 days later after this loading dose
Regular therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles, given until progression of disease requiring cytotoxic therapy, lack of adherence to protocol (including HAART), or patient-requested discontinuation
Supportive medications:
- "Antihypertensive therapy was initiated for systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg persisting for more than 1 week or for systolic blood pressure greater than 210 mmHg or diastolic blood pressure greater than 120 mmHg at any time."
- "HIV-positive patients with CD4 count of less than 200 cells/μL received Pneumocystis jiroveci prophylaxis."
- "Mycobacterium avium prophylaxis was considered if CD4 count was less than 75 cells/μL."
- Patients with HIV/AIDS continued HAART
- Filgrastim (Neupogen) "used as clinically indicated"
References
- Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012 May 1;30(13):1476-83. doi: 10.1200/JCO.2011.39.6853. Epub 2012 Mar 19. link to original article contains verified protocol PubMed
Daunorubicin liposomal (DaunoXome)
Regimen, Gill et al. 1996
Level of Evidence: Phase III
- Daunorubicin liposomal (DaunoXome) 40 mg/m2 IV over 30 to 60 minutes on day 1
14-day cycles x minimum of 2 cycles; given until complete remission, unacceptable toxicity, disease progression, patient refusal, or death
Supportive medications:
- "No routine premedication was established by the protocol, but it could be provided at the discretion of the investigator"
References
- Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M,Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996 Aug;14(8):2353-64. link to original article contains verified protocol PubMed
Doxorubicin liposomal (Doxil)
Regimen, Northfelt et al. 1998
Level of Evidence: Phase III
- Doxorubicin liposomal (Doxil) 20 mg/m2 IV over 30 minutes once on day 1
14-day cycles x up to 6 cycles
Supportive medications:
- "Colony-stimulating factors (CSFs) were prescribed at the discretion of the investigators."
References
- Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998 Jul;16(7):2445-51. link to original article contains verified protocol PubMed
Etoposide (Vepesid)
Regimen, Evans et al. 2002
Level of Evidence: Phase II
- Etoposide (Vepesid) 50 mg PO once per day on days 1 to 7
14-day cycles
References
- Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol. 2002 Aug 1;20(15):3236-41. link to original article contains verified protocol PubMed